Baricitinib (Olumiant▼): increased risk of diverticulitis, particularly in patients with risk factors

Cases of diverticulitis (DV) and GI perforation have been reported in patients taking baricitinib; most, but not all, cases occurred in patients on concomitant medicines linked to increased risk of DV, therefore baricitinib should be used with caution in these particular groups.


Medicines and Healthcare products Regulatory Agency